Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$7.30 -2.5%	$6.63	$4.25 ▼ $9.85	$2.77B	0.41	4.58 million shs	1.98 million shs
KYMR Kymera Therapeutics	$41.82 -5.2%	$44.07	$19.44 ▼ $53.27	$3.15B	2.18	668,050 shs	354,781 shs
NRIX Nurix Therapeutics	$9.67 -4.6%	$11.36	$8.18 ▼ $29.56	$775.19M	2.14	731,796 shs	398,583 shs
SRRK Scholar Rock	$33.33 -6.1%	$35.73	$6.76 ▼ $46.98	$3.41B	0.48	1.91 million shs	1.93 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	0.00%	-10.30%	+10.58%	+67.92%	+27.44%
KYMR Kymera Therapeutics	0.00%	+3.45%	-3.69%	+49.54%	-7.70%
NRIX Nurix Therapeutics	0.00%	-4.16%	-11.98%	+4.32%	-57.79%
SRRK Scholar Rock	0.00%	+12.99%	-8.88%	+18.30%	+282.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Cos	4.3391 of 5 stars	2.0	4.0	4.0	2.8	3.3	1.9
KYMR Kymera Therapeutics	2.8717 of 5 stars	4.6	1.0	0.0	2.1	2.5	0.0
NRIX Nurix Therapeutics	2.5789 of 5 stars	4.4	2.0	0.0	2.3	0.8	0.0
SRRK Scholar Rock	4.5571 of 5 stars	4.6	0.0	4.4	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.00	Hold	$9.00	23.29% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	41.35% Upside
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	198.52% Upside
SRRK Scholar Rock	3.20	Buy	$45.75	37.26% Upside

Current Analyst Ratings Breakdown

Latest NRIX, BHC, KYMR, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	SRRK Scholar Rock	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$50.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$9.63B	0.28	$7.53 per share	0.97	($0.89) per share	-8.20
KYMR Kymera Therapeutics	$47.07M	63.53	N/A	N/A	$12.90 per share	3.24
NRIX Nurix Therapeutics	$88.38M	8.36	N/A	N/A	$7.44 per share	1.30
SRRK Scholar Rock	$33.19M	96.54	N/A	N/A	$3.94 per share	8.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	-$46M	$0.26	28.08	1.57	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.47	N/A	N/A	N/A	-616.03%	-31.60%	-27.12%	10/30/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	11/11/2025 (Estimated)

Latest NRIX, BHC, KYMR, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	141.90	1.31	0.98
KYMR Kymera Therapeutics	N/A	8.32	8.32
NRIX Nurix Therapeutics	N/A	6.82	6.82
SRRK Scholar Rock	0.21	6.33	6.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
KYMR Kymera Therapeutics	N/A
NRIX Nurix Therapeutics	N/A
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	8.12%
KYMR Kymera Therapeutics	16.01%
NRIX Nurix Therapeutics	7.40%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.07 million	Optionable
KYMR Kymera Therapeutics	170	71.50 million	60.05 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable

NRIX, BHC, KYMR, and SRRK Headlines

Recent News About These Companies

Wellington Management Group LLP Has $59.32 Million Holdings in Scholar Rock Holding Corporation $SRRK

August 25 at 4:41 AM | marketbeat.com

Nuveen LLC Takes Position in Scholar Rock Holding Corporation $SRRK

August 24 at 3:41 AM | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Research Coverage Started at Jefferies Financial Group

August 24 at 2:45 AM | americanbankingnews.com

Candriam S.C.A. Trims Stock Position in Scholar Rock Holding Corporation $SRRK

August 23 at 7:07 AM | marketbeat.com

Aberdeen Group plc Sells 50,705 Shares of Scholar Rock Holding Corporation $SRRK

August 23 at 4:42 AM | marketbeat.com

Russell Investments Group Ltd. Purchases 182,859 Shares of Scholar Rock Holding Corporation $SRRK

August 23 at 4:26 AM | marketbeat.com

Scholar Rock Holding Corporation $SRRK Shares Acquired by Swiss National Bank

August 23 at 3:56 AM | marketbeat.com

Scholar Rock Holding Corporation $SRRK Stake Lifted by Vanguard Group Inc.

August 23 at 3:35 AM | marketbeat.com

Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD

August 21, 2025 | insidermonkey.com

Scholar Rock assumed with a Buy at Jefferies

August 21, 2025 | msn.com

A Closer Look at Scholar Rock (SRRK) Valuation Following Landmark Phase 3 Data and FDA Priority Review

August 21, 2025 | finance.yahoo.com

Lord Abbett & CO. LLC Boosts Holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 17, 2025 | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025 | businesswire.com

Scholar Rock publishes SAPPHIRE trial data in The Lancet

August 15, 2025 | msn.com

Scholar Rock Holding: Upcoming Milestone Approaches

August 13, 2025 | seekingalpha.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares Sold by Informed Momentum Co LLC

August 13, 2025 | marketbeat.com

Scholar Rock’s Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss

August 12, 2025 | msn.com

Analysts Offer Predictions for Scholar Rock FY2025 Earnings

August 11, 2025 | marketbeat.com

Wedbush Brokers Lower Earnings Estimates for Scholar Rock

August 11, 2025 | marketbeat.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts

August 11, 2025 | marketbeat.com

XTX Topco Ltd Takes Position in Scholar Rock Holding Corporation (NASDAQ:SRRK)

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX, BHC, KYMR, and SRRK Company Descriptions

Bausch Health Cos NYSE:BHC

$7.30 -0.19 (-2.54%)

Closing price 03:59 PM Eastern

Extended Trading

$7.36 +0.06 (+0.81%)

As of 07:57 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Kymera Therapeutics NASDAQ:KYMR

$41.82 -2.28 (-5.17%)

Closing price 04:00 PM Eastern

Extended Trading

$42.83 +1.01 (+2.42%)

As of 06:42 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$9.67 -0.47 (-4.64%)

Closing price 04:00 PM Eastern

Extended Trading

$10.24 +0.57 (+5.85%)

As of 07:50 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Scholar Rock NASDAQ:SRRK

$33.33 -2.16 (-6.09%)

Closing price 04:00 PM Eastern

Extended Trading

$32.90 -0.42 (-1.28%)

As of 07:12 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time